The stock of Mersana Therapeutics Inc. (NASDAQ:MRSN) decreased by -$0.01 on Tuesday to $1.30, down -0.38 percent. The last five days have seen an average of 1,764,927 shares of common stock traded. 20 times new highs were reached in the current year, with a fall of -$4.5550. The average number of shares traded over the last 20 days was 16,013,342, while the average volume over the last 50 days totaled 9,005,485.
MRSN stock dropped -63.65% since last month. On 07/27/23, the company’s shares reached a one-month low of $0.8014. The stock touched a high of $9.62 on 06/12/23, after rallying from a low of $0.80 in 52 weeks. The price of MRSN stock has declined by -77.73% or -$4.5550 this year, reaching a new high 20 times. Still, the stock price is down -86.43% from the 52-week high.
Insider Transactions
MRSN stock investors should be aware that Mersana Therapeutics Inc. (MRSN) stock had its last reported insider trading activity 110 days ago on Apr 27. On Apr 27, SVP, Chief Legal Officer Carvajal Alejandra sold 3,944 shares at $3.89 each. This transaction resulted in the insider making $15,342. On Jan 17, Protopapas Anna sold 17,346 shares at a price of US$5.74. After the transaction, the insider now owns 48,733 shares. SVP, Chief Sci.&Tech. Off. Lowinger Timothy B had earlier sold 6,233 shares on Jan 17 for $5.74 a share. The transaction was completed for $35,777.
Valuation Metrics
Beta for the stock is 1.42. There are also a few other valuation ratios worth considering, including the trailing price-to-sales (P/S) ratio of 3.70, the price-to-book (PB) ratio of 1.67.
Financial Health
For the three months ended June 29, Mersana Therapeutics Inc.’s quick ratio was 4.00, while its current ratio was 4.00, indicating its ability to pay off its debt. The company’s long-term debt to equity ratio for the quarter ending June 29 is 0.28, and the total debt to equity ratio is 0.28. Based on annual data, it had gross profit of $230.35 million and revenue of $26.58 million.
Investors will also look at the performance of the company’s management in order to determine the potential profitability of their investment. MRSN’s return on assets (ROA) during the last 12 months has been -68.50%. There was a -173.60% return on investment (ROI) in the past year. In the meantime, the return on equity (ROE) for the last 12 months was -255.90%.
Earnings Surprise
According to Mersana Therapeutics Inc.’s quarterly financial report for the quarter that ended June 29. A higher net income was reported in the quarter under review than the previous quarter. Net income for the quarter came in at $10.65 million, while revenues rose by 59.81% to $7.8 million. It was predicted that Mersana Therapeutics Inc.’s quarterly earnings would be -$0.47, but it ended up being -$0.44, beating the consensus by -6.80%. EBITDA was -$57.96 million for the quarter. At the end of Mersana Therapeutics Inc.’s most recent quarter ended June 29, its liabilities totaled 221.2 million, while its total debt was $35.11 million. Equity owned by shareholders amounts to $120.51 million.
Technical Picture
Here’s a quick look at Mersana Therapeutics Inc.’s (MRSN) price momentum from a technical perspective. As of 14 August, the RSI 9-day stood at 29.47%, suggesting the stock is oversold, with a 68.20% historical volatility rate.
The stochastic %K and %D were 38.24% and 21.99% respectively, while the average true range (ATR) was 0.2120. Based on the 14-day stochastic reading of 84.13%, the RSI (14) reading is 28.48%. On the 9-day MACD Oscillator, the stock is at 0.0628, and the 14-day reading is at 0.0873.
Analyst Ratings
Mersana Therapeutics Inc. (NASDAQ: MRSN) was downgraded by Robert W. Baird to a a Neutral rating in its latest research report. The stock was previously rated as a an Outperform. Analysts have assigned Mersana Therapeutics Inc. (MRSN) an Hold rating. MRSN is a stock that is recommended for selling by 1 brokerage firm, while 6 companies recommend holding. The stock is underweighted by 0 analysts. Among the analysts who rate the stock, 0 rates it overweight and 2 others recommend it as a buy.
What is MRSN’s price target for the next 12 months?
The current consensus forecast for the stock is between $1.00 and $4.00, with a median target price of $1.50. In analyzing these forecasts, the average price target given by analysts for Mersana Therapeutics Inc. (MRSN) is $2.00.
